Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts

Abhishek A. Mangaonkar, Naseema Gangat, Aref Al-Kali, Michelle A. Elliott, Kebede Begna, Curtis A. Hanson, Rhett P. Ketterling, Alexandra P. Wolanskyj-Spinner, William Hogan, Mark R Litzow, Mrinal M Patnaik

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multilineage dysplasia (MLD) based on the presence or absence of ring sideroblasts (RS). We performed this study to validate this change in the context of relevant gene mutations. Methods: WHO-defined MDS and MLD were identified with detailed clinical, cytogenetic and outcomes data. A 32-gene targeted exome sequencing panel was performed on bone marrow samples obtained at diagnosis. Results: Ninety eight patients were included; 59 (60%) MDS-MLD and 39 (40%) MDS-RS-MLD. There were no significant differences in the median overall survival (OS) in the two groups (25 months each, p = 0.6). Among the myeloid-relevant gene mutations, presence of ASXL1 (HR 2.5, p = 0.005) was identified as an adverse prognostic factor in a multivariate analysis. Conclusion: While segregation of MDS-MLD based on RS holds little prognostic relevance, ASXL1 mutational status significantly and independently predicts poor outcomes.

Original languageEnglish (US)
Pages (from-to)60-62
Number of pages3
JournalLeukemia Research
Volume71
DOIs
StatePublished - Aug 1 2018

Fingerprint

Myelodysplastic Syndromes
Mutation
Genes
Exome
Cytogenetics
Multivariate Analysis
Bone Marrow
Survival
Neoplasms

Keywords

  • ASXL1
  • Bone marrow morphology
  • MDS
  • MDS-MLD
  • MDS-RS
  • Multilineage dysplasia
  • Myelodysplastic syndromes
  • Prognosis
  • RCMD
  • Ring sideroblasts

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. / Mangaonkar, Abhishek A.; Gangat, Naseema; Al-Kali, Aref; Elliott, Michelle A.; Begna, Kebede; Hanson, Curtis A.; Ketterling, Rhett P.; Wolanskyj-Spinner, Alexandra P.; Hogan, William; Litzow, Mark R; Patnaik, Mrinal M.

In: Leukemia Research, Vol. 71, 01.08.2018, p. 60-62.

Research output: Contribution to journalArticle

Mangaonkar, Abhishek A. ; Gangat, Naseema ; Al-Kali, Aref ; Elliott, Michelle A. ; Begna, Kebede ; Hanson, Curtis A. ; Ketterling, Rhett P. ; Wolanskyj-Spinner, Alexandra P. ; Hogan, William ; Litzow, Mark R ; Patnaik, Mrinal M. / Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. In: Leukemia Research. 2018 ; Vol. 71. pp. 60-62.
@article{091519bead4f4f6aa7a0bd96065e125d,
title = "Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts",
abstract = "Introduction: The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multilineage dysplasia (MLD) based on the presence or absence of ring sideroblasts (RS). We performed this study to validate this change in the context of relevant gene mutations. Methods: WHO-defined MDS and MLD were identified with detailed clinical, cytogenetic and outcomes data. A 32-gene targeted exome sequencing panel was performed on bone marrow samples obtained at diagnosis. Results: Ninety eight patients were included; 59 (60{\%}) MDS-MLD and 39 (40{\%}) MDS-RS-MLD. There were no significant differences in the median overall survival (OS) in the two groups (25 months each, p = 0.6). Among the myeloid-relevant gene mutations, presence of ASXL1 (HR 2.5, p = 0.005) was identified as an adverse prognostic factor in a multivariate analysis. Conclusion: While segregation of MDS-MLD based on RS holds little prognostic relevance, ASXL1 mutational status significantly and independently predicts poor outcomes.",
keywords = "ASXL1, Bone marrow morphology, MDS, MDS-MLD, MDS-RS, Multilineage dysplasia, Myelodysplastic syndromes, Prognosis, RCMD, Ring sideroblasts",
author = "Mangaonkar, {Abhishek A.} and Naseema Gangat and Aref Al-Kali and Elliott, {Michelle A.} and Kebede Begna and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Wolanskyj-Spinner, {Alexandra P.} and William Hogan and Litzow, {Mark R} and Patnaik, {Mrinal M}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.leukres.2018.07.010",
language = "English (US)",
volume = "71",
pages = "60--62",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts

AU - Mangaonkar, Abhishek A.

AU - Gangat, Naseema

AU - Al-Kali, Aref

AU - Elliott, Michelle A.

AU - Begna, Kebede

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Wolanskyj-Spinner, Alexandra P.

AU - Hogan, William

AU - Litzow, Mark R

AU - Patnaik, Mrinal M

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Introduction: The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multilineage dysplasia (MLD) based on the presence or absence of ring sideroblasts (RS). We performed this study to validate this change in the context of relevant gene mutations. Methods: WHO-defined MDS and MLD were identified with detailed clinical, cytogenetic and outcomes data. A 32-gene targeted exome sequencing panel was performed on bone marrow samples obtained at diagnosis. Results: Ninety eight patients were included; 59 (60%) MDS-MLD and 39 (40%) MDS-RS-MLD. There were no significant differences in the median overall survival (OS) in the two groups (25 months each, p = 0.6). Among the myeloid-relevant gene mutations, presence of ASXL1 (HR 2.5, p = 0.005) was identified as an adverse prognostic factor in a multivariate analysis. Conclusion: While segregation of MDS-MLD based on RS holds little prognostic relevance, ASXL1 mutational status significantly and independently predicts poor outcomes.

AB - Introduction: The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multilineage dysplasia (MLD) based on the presence or absence of ring sideroblasts (RS). We performed this study to validate this change in the context of relevant gene mutations. Methods: WHO-defined MDS and MLD were identified with detailed clinical, cytogenetic and outcomes data. A 32-gene targeted exome sequencing panel was performed on bone marrow samples obtained at diagnosis. Results: Ninety eight patients were included; 59 (60%) MDS-MLD and 39 (40%) MDS-RS-MLD. There were no significant differences in the median overall survival (OS) in the two groups (25 months each, p = 0.6). Among the myeloid-relevant gene mutations, presence of ASXL1 (HR 2.5, p = 0.005) was identified as an adverse prognostic factor in a multivariate analysis. Conclusion: While segregation of MDS-MLD based on RS holds little prognostic relevance, ASXL1 mutational status significantly and independently predicts poor outcomes.

KW - ASXL1

KW - Bone marrow morphology

KW - MDS

KW - MDS-MLD

KW - MDS-RS

KW - Multilineage dysplasia

KW - Myelodysplastic syndromes

KW - Prognosis

KW - RCMD

KW - Ring sideroblasts

UR - http://www.scopus.com/inward/record.url?scp=85049805127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049805127&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.07.010

DO - 10.1016/j.leukres.2018.07.010

M3 - Article

C2 - 30015104

AN - SCOPUS:85049805127

VL - 71

SP - 60

EP - 62

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -